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ABSTRACT 41 
 42 
It is well recognized that atopic sensitisation is an important risk factor for asthma, both in adults 43 
and in children. However, the role of allergy in severe asthma is still under debate. The term 44 
“Severe Asthma” encompasses a highly heterogeneous group of patients who require treatment on 45 
steps 4–5 of GINA guidelines to prevent their asthma from becoming "uncontrolled", or whose 46 
disease remains "uncontrolled" despite this therapy. Epidemiological studies on emergency room 47 
visits and hospital admissions for asthma suggest the important role of allergy in asthma 48 
exacerbations. In addition, allergic asthma in childhood is often associated with severe asthma in 49 
adulthood. A strong association exists between asthma exacerbations and respiratory viral 50 
infections, and interaction between viruses and allergy further increases the risk of asthma 51 
exacerbations. Furthermore, fungal allergy has been shown to play an important role in severe 52 
asthma. Other contributing factors include smoking, pollution and work-related exposures. The 53 
“Allergy and Asthma Severity” EAACI Task Force examined the current evidence and produced 54 
this position document on the role of allergy in severe asthma. 55 
 56 
 57 
ABSTRACT WORD COUNT: 174 58 
  59 
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INTRODUCTION 60 
 61 
Numerous epidemiological studies have demonstrated that atopic sensitisation is a strong risk factor 62 
for asthma in childhood(1, 2) and adulthood(3), both in the developed(3) and in the developing 63 
countries(1, 2, 4), supporting the notion that asthma is in part an allergic disease. However, the role 64 
of allergy in severe asthma remains the issue of considerable controversy. The term “severe 65 
asthma” encompasses a highly heterogeneous group of patients, which is defined in various ways in 66 
the literature(5). Recent international guidelines define “severe asthma” as asthma which requires 67 
treatment at GINA steps 4–5 during the previous year or systemic corticosteroids (CS) for ≥50% of 68 
the previous year to prevent it from becoming ‘‘uncontrolled’’, or asthma which remains 69 
‘‘uncontrolled‘‘ despite this therapy, or controlled asthma that worsens on tapering high doses of 70 
inhaled corticosteroids (ICS), systemic CS or additional biologics(6). 71 
Asthma exacerbations are one of the key features of severe asthma. Emergency room visits and 72 
hospital admissions due to acute asthma attacks are increased in children who are sensitised and 73 
exposed to high levels of inhalant allergens in their homes, emphasising the importance of “allergy” 74 
in asthma exacerbations(7). The phenotypes of childhood onset allergic asthma and early 75 
sensitisation are often associated with severe asthma in adulthood(8). However, some data indicated 76 
that the proportion of severe asthma cases attributable to allergy may be overestimated, and that 77 
aetiological mechanisms other than allergy may be important in the pathogenesis of severe asthma. 78 
For example, numerous studies have reported a strong association between asthma exacerbations 79 
and respiratory viral infections, suggestive of a viral-induced mechanism. Rather than being 80 
mutually exclusive, viruses and allergens may interact in increasing the risk of asthma 81 
development(9).  82 
Furthermore, fungal sensitisation is strongly associated with severe asthma, hence, recently a new 83 
subtype of Severe Asthma with Fungal Sensitization (SAFS) has been proposed(10). 84 
Finally, the role of several co-factors, such as smoking, pollution and work-related exposures must 85 
be considered when evaluating a patient with severe asthma. 86 
The “Allergy and Asthma Severity” EAACI Task Force produced this position document on the 87 
role of allergy in severe asthma, searching the literature of the last 10 years in the main databases 88 
(MEDLINE, Scopus, ISI) and including milestone and important papers at the discretion of the 89 
different co-authors. 90 
 91 
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 92 
DEFINITION AND ROLE OF INHALANT ALLERGENS IN ASTHMA 93 
 94 
Atopy, allergy and asthma 95 
The association between atopy and asthma appears specific to inhalant allergens(4). In general, 96 
atopic sensitisation is defined either when allergen-specific serum IgE (sIgE) are detected, or a 97 
positive skin prick test (SPT) to extracts made from whole allergen sources(11, 12), often using 98 
arbitrary cut-off points of sIgE>0.35 KU/L, or a mean wheal diameter >3mm. These standard 99 
allergy tests have high sensitivity, but in themselves do not signify disease. For example, a 100 
considerable proportion of such defined sensitised individuals have no evidence of asthma(13), and 101 
a positive test in an asthmatic patient does not always result in clinical response upon allergen 102 
exposure. Thus, there is a difference between allergic asthma with asthma symptoms induced by 103 
exposure to a defined allergen, and asthma in a subject characterized as “sensitised” with no 104 
relation between allergen exposure and clinical reaction. It has been suggested that a positive 105 
allergy test (assessed either by sIgE or SPT) should not be considered as a sole diagnostic marker of 106 
atopic sensitisation(14). 107 
 108 
Quantification of atopic sensitisation increases the specificity in relation to asthma presence and 109 
severity  110 
The last decade has seen the shift in the way we interpret the results of IgE and SPTs. The sum of 111 
the levels of specific IgE antibodies (or the summative size of SPT wheals) to inhalant allergens is a 112 
better predictor of the onset, presence, persistence and severity of childhood asthma than the mere 113 
presence of a “positive allergy test”(15-17). The clinical importance of “quantitative atopic 114 
sensitisation” has been confirmed in subsequent studies in adult asthma(18). It is now recognized 115 
that quantification of atopic sensitisation in early life amongst young children with wheezing is one 116 
of the best discriminators to identify those who are at high risk of subsequent development of 117 
persistent asthma(19).  118 
Additionally, a clear quantitative relationship between the level of sIgE and the size of SPT 119 
responses has been observed in relation to asthma severity, both in adults and in children(20, 21). 120 
For example, one of the phenotypic characteristics of severe treatment-resistant asthma (STRA) in 121 
childhood is the large size of SPT wheals to inhalant and food allergens. In patients with STRA, 122 
results of sIgE measurements and SPTs are not always concordant, indicating the need to carry out 123 
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both tests(17, 20). The level of sIgE is also associated with an increased risk of severe asthma 124 
exacerbations requiring hospitalization among both children(17, 22) and  adults(23). Finally, it has 125 
been shown that there is a strong interaction between the levels of sIgE to inhalant allergens and 126 
respiratory virus infections in increasing the risk of severe asthma exacerbations requiring hospital 127 
admission(24), suggesting a synergism between quantitative sensitisation and respiratory virus 128 
infections. This synergism has been indirectly confirmed in a study showing that pre-seasonal anti-129 
IgE- targeted therapy with omalizumab decreases seasonal exacerbations of asthma (“back-to-130 
school asthma”), which are almost certainly (rhino)virus-induced(25). In contrast, a recent study 131 
showed that although impaired IFN-β and IFN-λ induction by rhinovirus was a feature of bronchial 132 
epithelial cells from highly sensitised children with STRA(26), there was no relationship between 133 
sensitisation and Th2-mediated inflammation with impaired interferon production, raising a 134 
possibility of two independent mechanisms (atopy-related and virus-related). 135 
All of the above data indicate that in the assessment of patients with asthma (including severe 136 
asthma), the results of specific IgE measurement and SPT are not mutually exclusive but 137 
complementary, and should not be reported as being “positive” or “negative”, but as the level of 138 
sIgE and the size of SPT wheal diameter (i.e., quantified). For SPTs, the size of the positive and 139 
negative control should be taken into account. Recent data suggest that diagnostic accuracy of 140 
specific IgE antibody measurement in the context of asthma and the distinction between “benign” 141 
atopy (i.e., sensitisation in the absence of allergic symptoms) and “pathologic” atopy (i.e., 142 
sensitisation related to allergic symptoms), may be improved by the measurement of allergen-143 
specific IgG antibody levels(27), although their measurement is not recommended routinely. 144 
 145 
Heterogeneity of atopic sensitisation 146 
It has recently been proposed that “atopic sensitisation” maybe an umbrella term for a collection of 147 
several different subgroups of sensitisation which differ in their association with asthma and other 148 
allergic diseases(14). Distinct subgroups (or classes) of sensitisation were described in one 149 
population-based birth cohort (Manchester Asthma and Allergy Study) by applying a machine 150 
learning approach with Bayesian inference to the SPTs and sIgE data collected longitudinally from 151 
early life to school age(28), and similar latent structure was subsequently described using 152 
comparable approach to longitudinal data on atopic sensitisation in another birth cohort (Isle of 153 
Wight study)(14). Children who would be considered sensitised using conventional definitions were 154 
clustered into four distinct subgroups characterised by a unique pattern of the responses to different 155 
allergens and the timing of onset of allergen-specific sensitisation(28) (Figure 1). Importantly, the 156 
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risk of asthma was increased more than 20-fold amongst children belonging to one of these 157 
subgroups (those sensitised to multiple allergens in early life - comprising less than one third of the 158 
sensitised children), but not amongst those in other classes(14, 28). Striking similarities were 159 
observed in the association between different subgroups of atopic sensitisation in these two cohorts 160 
in relation to asthma severity, with children in the subgroup of sensitisation characterised by IgE 161 
responses to multiple allergens in early life having higher FeNO levels, more hyperreactive airways, 162 
an increased risk of severe asthma exacerbations having significantly diminished lung function, 163 
compared to all other classes(14, 28, 29). It is of note however, that such subtypes (clusters/classes) 164 
of sensitisation can only be identified using statistical inference on longitudinal data(14, 28), and 165 
that differentiation between different clusters at any single cross-sectional point is not yet 166 
possible(30). Clinical translation of this important observation requires the development of specific 167 
and sensitive biomarkers which can be measured at the time of presentation to clinic and which aid 168 
differentiation between different sensitisation subgroups. Recent data indicate that IgE responses to 169 
individual allergenic molecules rather than whole allergen extracts may prove useful in 170 
differentiating the subtypes of sensitisation relevant to asthma onset and severity(31, 32). 171 
 172 
Progression from Atopic Dermatitis to Allergic Asthma – fact or myth? 173 
Although atopic dermatitis (AD) usually precedes allergic asthma or rhinitis, a clear causal 174 
relationship for the typical sequence in the development of these diseases – formerly termed as the 175 
‘atopic march’ – remains to be confirmed. Recent analysis among 10,000 children followed from 176 
birth to school age, has demonstrated that, whilst point prevalence data for the whole population 177 
may show a profile consistent with the atopic march, modelling within individual data over the life 178 
course shows seven different patterns, with >94% of children with symptoms (AD, wheeze and 179 
rhinitis) during childhood not following the atopic march profile(33). Therefore, the atopic march 180 
may be just an epiphenomenon of different allergic subtypes occurring at similar time points of the 181 
individual development (co-manifestation), e.g. early-life wheeze and early-life sensitization. 182 
Evidence from longitudinal studies suggests that approximately one-third of patients with AD 183 
develop asthma and two-thirds develop allergic rhinitis support the hypothesis of an underlying 184 
common mechanism. A review of four population-based cohort studies with a minimum of 80% 185 
follow-up, confirmed that early-life AD (especially IgE-associated AD) is a significant risk factor 186 
for developing asthma later in life (pooled OR 2.14; 95% CI 1.76–2.75)(34). Interestingly, in two of 187 
these cohorts, the significant association of early-life eczema and asthma disappeared when 188 
adjusted for early-life wheeze and sensitization, but was still present when adjustment was confined 189 
to early-life wheeze, suggesting that sensitization is a major common factor. It also points to a 190 
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putative mechanism where AD may increase the risk of subsequent sensitization, which in turn 191 
increases the risk of asthma.  192 
Filaggrin gene (FLG) mutations are associated both with atopic and nonatopic eczema starting in 193 
the first year of life. FLG mutations combined with eczema in the first year of life are associated 194 
with a later development of asthma and hay fever, and this may support the latter 195 
mechanism(35). This more modern view of the atopic march is furthermore strongly supported by 196 
recent data on the defective skin barrier function as the key factor for the pathogenesis of AD(36). 197 
Skin barrier dysfunction facilitates transdermal dehydration and infiltration of allergens, bacteria 198 
and bacterial toxins, thus inducing and enhancing allergen sensitization as a hallmark of the atopic 199 
march(37). Skin sensitization is followed by airway sensitization to the same allergen and is one of 200 
the most robust predictors for the development of childhood asthma(38). This is detailed further on 201 
in this review. In conclusion, there is evidence for the hypothesis linking AD as an initial (but 202 
probably not only) promoter of atopy/allergic sensitization with progression to asthma.  203 
 204 
Component-resolved diagnostics in asthma 205 
Recent advances in biochemistry and molecular biology have led to the isolation and 206 
characterisation of numerous allergenic proteins (components), facilitating the profiling of IgE 207 
reactivity to individual allergens at a molecular level. This new approach to allergy diagnosis has 208 
been termed molecular diagnosis or component-resolved diagnostics (CRD), and its 209 
commercialisation has facilitated the development of products in which sIgE to >100 allergen 210 
components can be measured simultaneously. Component resolved diagnostics may help in 211 
identifying patients at risk of developing more severe disease(31, 32). Sensitization to mite 212 
allergens Der p 2 and Der f 2 has been reported to be more common in severe asthma (39). Latex 213 
allergy and asthma is another example were sensitization to 3 out of 12 recombinant natural rubber 214 
antigens (5, 6.01/6.02), was strongly linked to those with latex sensitization and asthma (40) 215 
The role of these novel tools in clinical practice and how best to interpret the complex data they 216 
generate is the subject of ongoing debate(41, 42). It has recently been reported that CRD may 217 
improve the assessment of asthma(31, 43), and help better understanding the role of allergy in 218 
severe asthma in childhood(44). However, it is likely that better interpretation algorithms are 219 
needed to capitalise fully on the potential of this exciting new technology(43).  220 
 221 
 222 
 223 
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 224 
SIMILARITIES AND DISTINCTIONS BETWEEN ADULT AND PAEDIATRIC SEVERE 225 
ASTHMA 226 
 227 
A fundamental feature of severe asthma in both adults and children is its heterogeneity, with 228 
multiple clinical phenotypes(6, 45-50). When unsupervised cluster analyses are performed, whether 229 
in adults or children, several common clinical features provide phenotypic distinctions, including 230 
the age of onset of disease, presence of co-morbidities, differences in lung function and the degree 231 
of atopic sensitisation(50-52). Using this approach, it appeared that the role of atopic sensitisation 232 
might be more important in the pathogenesis of severe asthma in early life. Severe atopy, 233 
characterised by polysensitisation and high specific IgE levels, is integral to childhood severe 234 
disease, such that >85% of children with severe asthma are severely atopic(53). In concurrence, 235 
when phenotypic clusters are investigated in adults with severe asthma, the single most important 236 
factor that repeatedly distinguishes the importance of allergy is age of disease onset(45). The 237 
phenotype of childhood onset asthma is robust, is repeatedly identified in adult cluster analyses and 238 
is undoubtedly associated with very severe allergic disease(8). In contrast, severe adult onset 239 
asthma is a distinct phenotype that is usually not characterised by atopic sensitisation, but often 240 
associated with nasal polyposis and sputum eosinophilia(54). 241 
 242 
Atopy and paediatric severe asthma 243 
The importance of early atopic sensitisation contributing to childhood severe asthma is reflected in 244 
the evidence of early sensitisation in preschool children being the main predictor of asthma 245 
development by school age(19, 55). In addition, even though recurrent wheezing episodes caused 246 
by rhinovirus infections in the first 3 years of life strongly predict asthma development(56), early 247 
atopic sensitisation is the main risk factor determining progression to asthma(56). Moreover, the 248 
pattern of atopic sensitisation to inhalant allergens, in particular to perennial ones, and the level of 249 
specific IgE increase asthma risk(57). 250 
The significant contribution of allergy to the pathogenesis of paediatric severe asthma is apparent 251 
from the clinical features that distinguish patients with difficult asthma (who have underlying 252 
modifiable factors) from those with genuine severe therapy resistant asthma (STRA)(58). 253 
Significantly, more patients with STRA are polysensitised, and have food allergy. Perhaps the most 254 
important distinctive feature of STRA becomes apparent when atopic sensitisation is quantified(18, 255 
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59). Patients with severe asthma have a much higher allergic burden(51, 60) suggesting that atopic 256 
sensitisation plays a critical role in the development, progression and persistence of paediatric 257 
severe disease.  258 
 259 
Adult onset, severe asthma: an age-specific phenotype 260 
Adult onset asthma is a recognised phenotype of severe asthma, presenting with several sub-261 
phenotypes(61). Although it is considered predominantly non-allergic, a significant proportion of 262 
patients with adult onset disease are atopic (34%)(61). In those with severe disease, a worse 263 
prognosis is apparent in smokers and ex-smokers(62), and, as described later on, smoke exposure 264 
has a detrimental effect on severe asthma, resulting in reduced corticosteroid responsiveness, 265 
regardless of age(63). Distinguishing and specific features of adult onset asthma include association 266 
with co-morbidities, such as obesity, and a predominance in middle-aged women(64). The adult-267 
onset obese, female predominant phenotype is characterised by the absence of inflammation and 268 
atopic sensitisation. Although this specific set of features is seen in adults, mechanisms resulting in 269 
obesity-associated asthma may not be dissimilar in children and adults. Children with severe asthma 270 
who have a higher BMI are less likely to have detectable inflammatory Th2 cytokines and have 271 
relatively higher lung function than those with lower BMI(53). 272 
Another common adult-onset phenotype includes severe (non-allergic) eosinophilic phenotype, 273 
which is the most prevalent phenotype of severe asthma in adults, associated with aspirin 274 
sensitivity, nasal polyposis and eosinophilia, all persisting despite the treatment with high doses of 275 
inhaled corticosteroids(54). Innate immune mechanisms underlying this phenotype have recently 276 
been proposed since it has become apparent that patients respond to anti-IL-5 antibody 277 
therapies(65). 278 
 279 
Contribution of allergy to mechanisms underlying severe asthma 280 
The role of allergy in severe asthma needs to be understood to help identify underlying mechanisms 281 
of disease progression which will impact both on the choice of add-on therapies and on the 282 
discovery of novel therapeutics. Even though the majority of children and adults with early-onset 283 
severe asthma are sensitised, it is interesting that not all respond to treatment with omalizumab(66, 284 
67)suggesting several different mechanisms contributing to the development of different allergic 285 
phenotypes. 286 
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Typically, the allergic asthma phenotype is associated with eosinophilia, elevated serum IgE and 287 
Th2 cytokines. However, in adult-onset asthma, eosinophilia may be present without overt evidence 288 
of allergy(65). The limited contribution of allergy to disease persistence is apparent in adults with 289 
severe asthma who show a non-allergic, inhaled corticosteroid “resistant” eosinophilic phenotype, 290 
which responds to systemic CS and targeted therapy with anti-IL-5 (mepolizumab)(68). Novel 291 
mechanisms that may contribute to this adult-onset phenotype include epithelial innate cytokines 292 
that directly induce the recruitment of innate lymphoid cells which secrete Th2/“allergic” cytokines 293 
without the generation of IgE or an adaptive immune response(69). Interestingly, even though it is 294 
thought that this is an innate, non-adaptive, non-allergic immune response, all murine experimental 295 
models investigating the role of innate cytokines in asthma pathogenesis used allergen exposure as 296 
the stimulus, suggesting allergy still plays a central mechanistic role in this phenotype(70). It is 297 
possible that allergy is a risk factor in the development of adult-onset “non-allergic” eosinophilic 298 
asthma, but the clinical manifestation of asthma changes with time and age, whereby it is less 299 
overtly “allergic”, but remains eosinophilic. 300 
In asthma, the effect of innate immunity eliciting Th2 responses seems to be strongly related to IL-301 
33(71), and is especially associated with severe disease. IL-33 expression is increased in bronchial 302 
tissue from both adults(72, 73) and children(74)with severe asthma. Other important features of 303 
innate cytokines that may contribute to the pathogenesis of severe disease in both adults and 304 
children include their role in (relative) corticosteroid resistance(74) and their association with 305 
angiogenesis and airway remodelling, in particular as regards IL-25 (74-76).  306 
An interesting distinction of adult asthma phenotypes based on gene expression of periostin by 307 
airway epithelial cells includes the separation in Th2 high and Th2 low phenotypes(77), and the 308 
utility of this biomarker to predict therapeutic response to antibodies that block Th2 cytokines(78). 309 
Although biomarkers that allow such distinctions have not yet been identified in children, and while 310 
in general children with severe asthma have low or undetectable Th2 cytokines in airway samples, 311 
there is a sub-group in whom Th2 cytokines can be detected(53), emphasising similarities between 312 
adult and childhood disease. 313 
 314 
 315 
CROSS-TALK BETWEEN ENVIRONMENTAL FACTORS, ATOPIC SENSITISATION 316 
AND ASTHMA 317 
 318 
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The airway epithelial barrier 319 
Environmental stimuli, such as viruses, bacteria and air pollutants, are known activators of innate 320 
immunity and may thus enhance the airway inflammation in asthmatic patients. Allergens, apart 321 
from being recognised by the adaptive immunity, may also play a crucial role in activating innate 322 
immunity through proteases, biologically active glycolipids and enzymes(79). The airway epithelial 323 
barrier, for long time perceived as only a mechanical barrier, is now also recognised as a gate to 324 
initiate atopic sensitization and allergic inflammation(80). Epithelial cells recognise the allergens 325 
with the help of pattern recognition receptors and produce an innate immune response. As apical 326 
junctional complexes between the airway epithelium cells are being disrupted by viral infections 327 
and inhaled airway irritants, they facilitate the entry of allergens from the lumen to be presented to 328 
the dendritic cells.  329 
In bronchial biopsies and brushings especially from more severe asthmatic patients, airway 330 
epithelium cells showed structural and functional defects in apical junctional complexes compared 331 
to healthy controls(81). However, this reduced barrier function was found to be reversible by 332 
epidermal growth factor (EGF) treatment(81). 333 
 334 
The role of microbiota 335 
Early life airway and gut microbiota and influencing factors such as the delivery method, feeding 336 
practices, antibiotic use and living environment were shown to be related with allergic asthma 337 
development(82). Both the microbial burden and diversity within the lower airways were shown to 338 
be significantly higher in suboptimally controlled asthmatic patients compared to healthy 339 
individuals(83). Protobacteria species significantly predominated in asthmatic patients using 340 
inhaled corticosteroids and showed the strongest correlations with the degree of bronchial 341 
hyperresponsiveness(82). In addition, corticosteroid resistance in asthmatic patients was found to be 342 
related to airway microbiome diversity(84). In these patients, Haemophilus parainfluenza 343 
dominated the microbiome, and was shown to inhibit the response to corticosteroid treatment 344 
compared to corticosteroid responsive asthmatic patients. Microbial diversity was also shown to 345 
increase the risk of rhinovirus-induced asthma exacerbations in children(85). If rhinovirus existed 346 
concomitantly with Moraxella catarrhalis, Streptococcus pneumoniae, or Haemophilus influenzae 347 
within the airways, the risk of asthma exacerbations was found to be significantly increased as 348 
compared to children without these pathogens. 349 
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 350 
Viruses 351 
The interaction between viral lower respiratory tract infections (LRTI) and atopic sensitization has 352 
been recognized as a major factor contributing to asthma development and exacerbation(86, 87). 353 
Birth cohort studies provide strong evidence for a synergistic effect of viral LRTI and atopic 354 
sensitization on asthma inception particularly in predisposed children(56, 88). Other factors 355 
reported to increase the risk of asthma development include the type of virus (more than 10-fold 356 
increased risk for asthma development with rhinovirus compared to 5-fold with respiratory 357 
syncytial virus), the severity of viral LRTI, the age during viral LRTI and the atopic 358 
predisposition(89). Very recently, the number of respiratory episodes in the first years of life, but 359 
not the particular viral trigger, was reported to be associated with later asthma development(90). 360 
Respiratory viral infections in combination with atopic sensitisation and exposure to allergens 361 
increase the risk of hospital admission due to asthma exacerbation both in children(91) and 362 
adults(92). Rhinoviruses (RV), especially RV-C group, are the most frequent viruses detected 363 
during an asthma exacerbation(22)including severe asthma exacerbations with near fatal and fatal 364 
asthma(23). Also, allergic asthmatic individuals experience more severe and prolonged LRTI 365 
symptoms with RV infection compared to non-atopic healthy controls(93). Biological mechanisms 366 
including impaired innate or altered adaptive immune function, abnormal airway structure and 367 
function following prior infections, genetic influences and extrinsic factors, such as maternal 368 
smoking, air pollution and nutritional factors (vitamin D), may explain the altered immune response 369 
to viral infections in asthmatic/allergic patients(87). Recently, antibody titers to species specific RV 370 
infection in children during asthma exacerbation showed that antibody response to RV-C is low 371 
even when the virus was detected, pointing to a divergent and possibly less efficacious immune 372 
response to this subtype compared to RV-A and B(94). The association of susceptibility to RV 373 
infection in asthma was also investigated in human bronchial epithelial cells showing impaired 374 
interferon production to the virus in severe therapy resistant allergic asthmatic children(26) but 375 
normal responses in well controlled asthmatic adults who were mostly atopic(95). In contrast to RV 376 
data, interferon responses to influenza A virus and RSV in human bronchial epithelial cell cultures 377 
were preserved in adults with mild to severe asthma(96).  378 
 379 
Outdoor, indoor and food allergens 380 
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Relationships between different types of allergens (outdoor, indoor, food) and the development and 381 
severity of allergic disease, including asthma, have been studied(97). For instance, pollen allergy 382 
has been found to be interrelated with various food allergies, digestive system Th2-inflammation 383 
and asthma(98, 99). Cross-reactivity between pollen and several plant-derived foods, nuts, and 384 
fruits has been well established(98). Food allergy without concomitant asthma has been found to be 385 
associated with increased nonspecific bronchial  hyperresponsiveness(100, 101), while several 386 
studies report that children with asthma and concomitant food allergy have more severe disease, 387 
poorer control, greater morbidity, and require more anti-asthma medications(102, 103). 388 
The most common indoor allergens associated with asthma include house dust mites, domestic 389 
animals (cats, dogs), and cockroaches(97, 104), while fungi can be found both indoor and outdoor. 390 
In a cohort of 300 asthmatic children (aged 4-12 y), higher Der p 1 and pet allergen levels were 391 
found to be associated with greater asthma severity(105). 392 
Fungal exposure is universal and fungi can be linked to asthma in a variety of ways. Fungal allergy 393 
drives asthma severity and long-term or uncontrolled fungal infections are associated with a poor 394 
control of asthma, complications such as bronchiectasies and chronic allergic bronchopulmonary 395 
aspergillosis (ABPA)(106).  In the general asthma population, sensitization to moulds ranges from 7 396 
to 20%, in severe asthma patients from 35 to 75%, being 54-91% in life-threatening asthma 397 
population(107-111). The first evidence of the link between the severity of asthma and fungal 398 
sensitisation dates to 1978, when Schwartz et al. demonstrated a relationship between asthma 399 
severity and Aspergillus spp sensitisation(112). Alternaria or Cladosporium spp sensitisation was 400 
associated with asthma severity in the European Community Respiratory Health Survey. 401 
Furthermore, a recent paper has shown that fungal sensitisation in children with persistent asthma is 402 
associated with disease severity(113)and a 2014 review has shown increasing evidence that 403 
sensitized asthmatic children may be susceptible to asthma exacerbations when exposed to outdoor 404 
fungal spores and that the severity of exacerbation may vary with different fungi species(114). 405 
The term “Severe Asthma with Fungal Sensitisation” (SAFS) was introduced by Denning et al. in 406 
2006, to describe those patients who have persistent severe asthma (despite standard treatment) and 407 
evidence of fungal sensitisation, as defined by positive SPT, or fungus or fungal antigen-specific 408 
sIgE, and do not meet the criteria for ABPA(10). Proposed classification by an EAACI Task Force 409 
sets the total IgE cut-off at <1000 IU/ml for SAFS and >1000 IU/ml for ABPA. ABPA was 410 
accepted as an endotype(115), while SAFS remains a pragmatic definition(106). ABPA may 411 
develop in asthmatics with a genetic predisposition and therefore SAFS may have the same 412 
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background. Carefully genotyping patients with different forms of asthma may allow a better 413 
understanding of this disease. 414 
“Trichophyton Asthma” is another clinical entity, where inhalation or the presence of cutaneous 415 
infection (athlete’s foot, onychomycosis) in sensitised asthmatics is associated with disease 416 
severity(106, 116). 417 
 418 
Smoking 419 
Cigarette smoking itself may influence asthma, as it accelerates lung function decline(117), impairs 420 
the response to CS (both inhaled and oral)(118), increases airway oxidative stress(119),  perpetuates 421 
symptoms despite of treatment(120) and induces the change of inflammatory phenotypes into more 422 
aggressive ones(121),  thereby resulting in a more severe disease(122). 423 
Smoking also increases serum IgE levels, especially in men(123). This may result in an increased 424 
risk of allergic sensitisation, at least for occupational allergens(124). However, the relationship 425 
between cigarette smoking and allergy in severe asthma is still debated: some studies identify 426 
smoking as a risk factor for allergic asthma(125), while others show a lower prevalence of atopic 427 
sensitisation in smoking patients with severe asthma(121). According to a large epidemiological 428 
survey (ECRHS II), smoking was more strongly associated with severe asthma in men than in 429 
women, particularly if they were sensitised to moulds (Cladosporium), house dust mites or 430 
cats(126). Even more conflicting data come from studies on the effect of passive smoking on the 431 
risk of development of atopic sensitisation(127). 432 
Cigarette smoking usually results in a more neutrophilic airway inflammation, which is less 433 
responsive to ICS(121). Accordingly, alveolar macrophages from smokers have a reduced cellular 434 
CS responsiveness, which is associated with reduced histone deacetylase activity, an essential 435 
molecule for anti-inflammatory genes transcription(63, 128). In fact, they show an elevated 436 
glucocorticoid receptors (GR) ratio in PBMC which is in favour of GR-β (not able to induce any 437 
transcriptional activity) compared to GR-α (the active isoform with anti-inflammatory effects)(129). 438 
These molecular events make smoking asthmatics less responsive to CS, currently the standard 439 
controller therapy for asthma, leading them to a more probable evolution to severe asthma (figure 440 
2). 441 
Recently, a new distinct phenotype of severe asthma has been identified in frequent exacerbators, 442 
and history of smoking seems to be a risk factor for this phenotype(130). A novel risk score for 443 
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asthma exacerbations developed and validated by Bateman et al. supports the evidence that 444 
smoking status is a main predictor for uncontrolled asthma(131). Despite this well-known 445 
relationship, active smoking is still surprisingly common among asthmatics(132). More efficient 446 
smoking prevention programs and smoking cessation campaigns should be carried out to try to 447 
reduce the risk of developing severe asthma. Moreover, most clinical trials with new drugs aimed 448 
for severe asthma have been conducted in non-smoking patients, which results in incomplete 449 
knowledge on the efficacy of such therapeutic approaches in smokers. Large “real life” studies in 450 
severe asthma including smoking asthmatics should be encouraged. The complex relationship 451 
between cigarette smoking and atopic sensitisation increasing the risk of severe asthma should be 452 
better investigated as only few and conflicting data are presently available. However, this 453 
relationship remains difficult to address, particularly in cross-sectional studies, because of the 454 
potential selection bias (e.g. “healthy smoker effect”)(133). Prospective studies in lifetime smokers 455 
with lifetime smoking are more appropriate to properly examine the relationships between smoking 456 
and severe asthma. 457 
 458 
Pollution 459 
The health effects caused by outdoor air pollution have been intensively studied during the last 460 
decades. The term “outdoor air pollution” involves particulate matter (PM), gaseous pollutions 461 
(nitrogen dioxide, sulphur dioxide and ozone) and traffic-related air pollution (elemental and carbon 462 
black, road dust)(134). 463 
Increased exposure to ultrafine particles and carbon monoxide within the previous 4-7 days was 464 
associated with increased relative odds of a paediatric asthma visit(135). Other studies also indicate 465 
that sudden increase or decrease of exposure to air pollution may affect asthmatic symptoms or 466 
emergency department visits(136-138). Indeed, a decrease in the number of acute asthma events of 467 
over 40% was found after reduction of air pollution during summer Olympic games(138). So far, 468 
these studies were performed in children and included only a relatively low number of individuals. 469 
Larger scale studies also demonstrated an adverse effect of outdoor air pollution on lung 470 
function(139-141). A multicenter birth cohort study (ESCAPE) showed an association between 471 
estimated levels of NO2 and PM2.5and decreases in FEV1(139). In another birth cohort study 472 
(MAAS), lifetime exposure to PM10 and NO2 was associated with significantly less growth in FEV1 473 
over time(140). In the same cohort, no association was found between long-term exposure to PM10 474 
and NO2 and the prevalence of asthma or wheeze(142). In adult asthmatics, exposure to NO2 and 475 
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PM10 was associated with lower measures of FEV1 and FVC(143)and exposure to ozone and PM10 476 
increased the risk of uncontrolled asthma(144). Overall, these studies thus provide evidence of an 477 
inverse association between outdoor air pollution and lung function (Table 1). Whether asthma 478 
severity is directly affected by outdoor air pollution is unclear. 479 
Several studies showed a positive association between exposure to air pollution during infancy and 480 
sensitisation to inhalant allergens(145-147). Although the mechanism underlying this association is 481 
not fully understood, some evidence suggests that ultrafine carbon black particles can directly 482 
induce maturation of dendritic cells in vitro(148), thereby facilitating sensitisation to inhalant 483 
allergens. Alternatively, airborne pollutants can induce the influx of inflammatory cells to the lungs, 484 
which might then lower the threshold for sensitisation. Indeed, it has recently been shown that 485 
allergen-specific Th2/Th17 cells accumulate in the lungs of mice exposed to both diesel exhaust 486 
particles and house dust mite extract(149). Diesel exhaust particles may also produce other 487 
immunological effects(150, 151) (Table 2). Furthermore, exposure to moderate air pollution during 488 
late pregnancy was found to cause increased cord blood IL-1β(152). A recent meta-analysis, 489 
however, showed no clear overall association between air pollution exposure and the development 490 
of sensitisation in children up to 10 years of age(153). 491 
In summary, in multi-sensitised asthmatics, daily exposure to allergens in combination with other 492 
enhancing factors, including viral infections, environmental smoking, and/or pollution, will finally 493 
determine the asthma course and severity. 494 
 495 
Occupational/Work-Related 496 
Severe asthma may occur in patients affected by Work-Related Asthma (WRA).WRA encompasses 497 
both Occupational Asthma (OA), defined as “asthma caused by the workplace” and “Work-498 
Exacerbated Asthma” (WEA), occurring in patients with pre-existing or concurrent asthma and 499 
exacerbated by different work-related factors (i.e. aeroallergens, exercise, irritants)(154). OA can be 500 
further divided into two subtypes: an allergic form (90% of all OA)(155), caused both by an IgE-501 
mediated mechanism towards high (HMW) and low (LMW) molecular weight agents(106), and a 502 
non-IgE mediated form (Non-Allergic, Irritant-Induced [Occupational] Asthma (IIOA)), towards 503 
specific LMW agents in which the mechanism has not been characterized yet. The non-allergic 504 
IIOA can be further divided into the “Reactive Airway Dysfunction Syndrome” (RADS) and the 505 
“IIOA after multiple exposures”. The first occurs after an acute, single exposure to very high 506 
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concentrations of irritating substances(156), while the second follows multiple exposure to irritants; 507 
in this subtype, onset of asthma can follow the exposures after some time(157, 158). 508 
WRA should be suspected in patients whose asthma worsens while working or begin at work. Here 509 
a detailed occupational and medical history is fundamental(159, 160), while a clinical history only 510 
shows a low specificity in the diagnosis of OA(161). The investigation of WRA follows a well-511 
defined protocol based on confirmation of bronchial asthma, work-related bronchoconstriction, 512 
sensitisation to occupational agents and on the confirmation of the causal role of occupational 513 
agents, being sensitisation per se not indicative of clinical symptoms(162) (Figure 3). Baseline 514 
spirometry is mandatory and it is strongly recommended that this should be complemented with 515 
non-specific bronchial hyperreactivity assessment with direct or indirect challenges. In individuals 516 
with suspected WRA, presenting with a normal respiratory function and/or negative methacholine 517 
challenge testing, serial lung function measurements and assessment of non-specific bronchial 518 
hyperreactivity are strongly recommended(162, 163). Additionally, spirometry can be performed 519 
during a work shift (Cross-shift spirometry). Furthermore, serial measurements of peak flow 520 
expiratory rate (serial PEFR) have been used to objectively confirm the link between the workplace 521 
and the asthmatic symptoms(164). Skin prick testing completes the diagnostic work-up, and the 522 
selection of specific allergens related to the individual’s job is fundamental. Specific IgE evaluation 523 
is also of importance. The role of atopic mechanisms in severe occupational asthma has been 524 
confirmed by a recent study where treatment with omalizumab was successful in 90% of severe 525 
occupational asthma patients due to HMW and LMW agents, such as flour, animal dander, mites, 526 
moulds, isocyanate or acrylates(165). It is worth noting that, at least in OA, allergen exposure levels 527 
represent the major determinants both for the disease as such and for the severity of asthma(166, 528 
167). Finally, specific inhalation challenges (SICs) or workplace inhalation challenges, 529 
complemented by the assessment of airway inflammation by induced sputum and FeNO may be 530 
considered. 531 
Diagnosis of IIOA follows a well-defined protocol described in a recent EAACI Task Force 532 
document(158).  533 
 534 
 535 
CONCLUSION 536 
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There is increasing evidence for the important, but not exclusive, role of allergy in severe asthma. 537 
Although some recent reports demonstrate that allergy may play only a limited role, this is likely 538 
not true for childhood disease, where early atopic sensitisation is critical in determining the severity 539 
of disease. 540 
Mechanistic implications of co-factors interacting with allergy and asthma, such as virus infections, 541 
pollution, smoking, and work-related exposures, still need to be completely uncovered to allow the 542 
discovery of novel therapeutic targets. 543 
 544 
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Figure 1.  For those children who suffered a hospital admission with wheeze or asthma after age 3 
years, a highly significant increase in the risk was seen only among children in the multiple early 
sensitisation subgroup (HR 9.2; 95% CI, 3.5–24; P < 0.001), but not other atopy classes.  
From (28): Simpson A, Tan VY, Winn J, et al. Beyond atopy: multiple patterns of sensitization in 
relation to asthma in a birth cohort study. Am J Respir Crit Care Med 2010;181(11):1200-6, with 
permission 
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Table 1: Main pollutants and examples of their effects on respiratory function. 
Pollutant Outcome 
  
Nitrogen dioxide (NO2) Decreased FEV1(139) 
 Less growth of FEV1 over time(140) 
 Lower measures of FEV1(143) 
 Lower measures of FVC(143) 
PM2.5 Decreased FEV1(139) 
PM10 Less growth of FEV1 over time(140) 
 Lower measures of FEV1(143) 
 Lower measures of FVC(143) 
 Increased risk of uncontrolled Asthma(144) 
Ozone (O3) Increased risk of uncontrolled Asthma(144) 
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Table 2: Pollutants and examples of their effects on allergic inflammation 
Pollutant Outcome 
  
Ultrafine Carbon Black Particles Induced maturation of Dendritic Cells in vitro (148) 
Diesel Exhaust Particles and 
House dust Mite Extract 
Increased allergen-specific IgE and other cardinal features of 
asthma (150) 
 Accumulation of allergen-specific Th2/Th17 cells in lungs 
(149) 
 Both Th2 and ILC2 contribute to DEP-enhanced airway 
inflammation (151) 
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Figure 2: Influence of smoking and atopy in determining more severe asthma. 
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Figure 3: Allergic Occupational Asthma: diagnostic flow-chart. 
From: Moscato G, Pala G, Barnig C, De Blay F, Del Giacco SR, Folletti I, et al. EAACI consensus 
statement for investigation of work-related asthma in non-specialized centres. Modified from: 
Allergy. 2012;67(4):491-501, with permission. 
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ABSTRACT 
 
It is well recognized that atopic sensitisation is an important risk factor for asthma, both in adults 
and in children. However, the role of allergy in severe asthma is still under debate. The term 
“Severe Asthma” encompasses a highly heterogeneous group of patients who require treatment on 
steps 4–5 of GINA guidelines to prevent their asthma from becoming "uncontrolled", or whose 
disease remains "uncontrolled" despite this therapy. Epidemiological studies on emergency room 
visits and hospital admissions for asthma suggest the important role of allergy in asthma 
exacerbations. In addition, allergic asthma in childhood is often associated with severe asthma in 
adulthood. A strong association exists between asthma exacerbations and respiratory viral 
infections, and interaction between viruses and allergy further increases the risk of asthma 
exacerbations. Furthermore, fungal allergy has been shown to play an important role in severe 
asthma. Other contributing factors include smoking, pollution and work-related exposures. The 
“Allergy and Asthma Severity” EAACI Task Force examined the current evidence and produced 
this position document on the role of allergy in severe asthma. 
 
 
ABSTRACT WORD COUNT: 174 
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INTRODUCTION 
 
Numerous epidemiological studies have demonstrated that atopic sensitisation is a strong risk factor 
for asthma in childhood(1, 2) and adulthood(3), both in the developed(3) and in the developing 
countries(1, 2, 4), supporting the notion that asthma is in part an allergic disease. However, the role 
of allergy in severe asthma remains the issue of considerable controversy. The term “severe 
asthma” encompasses a highly heterogeneous group of patients, which is defined in various ways in 
the literature(5). Recent international guidelines define “severe asthma” as asthma which requires 
treatment at GINA steps 4–5 during the previous year or systemic corticosteroids (CS) for ≥50% of 
the previous year to prevent it from becoming ‘‘uncontrolled’’, or asthma which remains 
‘‘uncontrolled‘‘ despite this therapy, or controlled asthma that worsens on tapering high doses of 
inhaled corticosteroids (ICS), systemic CS or additional biologics(6). 
Asthma exacerbations are one of the key features of severe asthma. Emergency room visits and 
hospital admissions due to acute asthma attacks are increased in children who are sensitised and 
exposed to high levels of inhalant allergens in their homes, emphasising the importance of “allergy” 
in asthma exacerbations(7). The phenotypes of childhood onset allergic asthma and early 
sensitisation are often associated with severe asthma in adulthood(8). However, some data indicated 
that the proportion of severe asthma cases attributable to allergy may be overestimated, and that 
aetiological mechanisms other than allergy may be important in the pathogenesis of severe asthma. 
For example, numerous studies have reported a strong association between asthma exacerbations 
and respiratory viral infections, suggestive of a viral-induced mechanism. Rather than being 
mutually exclusive, viruses and allergens may interact in increasing the risk of asthma 
development(9).  
Furthermore, fungal sensitisation is strongly associated with severe asthma, hence, recently a new 
subtype of Severe Asthma with Fungal Sensitization (SAFS) has been proposed(10). 
Finally, the role of several co-factors, such as smoking, pollution and work-related exposures must 
be considered when evaluating a patient with severe asthma. 
The “Allergy and Asthma Severity” EAACI Task Force produced this position document on the 
role of allergy in severe asthma, searching the literature of the last 10 years in the main databases 
(MEDLINE, Scopus, ISI) and including milestone and important papers at the discretion of the 
different co-authors. 
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DEFINITION AND ROLE OF INHALANT ALLERGENS IN ASTHMA 
 
Atopy, allergy and asthma 
The association between atopy and asthma appears specific to inhalant allergens(4). In general, 
atopic sensitisation is defined either when allergen-specific serum IgE (sIgE) are detected, or a 
positive skin prick test (SPT) to extracts made from whole allergen sources(11, 12), often using 
arbitrary cut-off points of sIgE>0.35 KU/L, or a mean wheal diameter >3mm. These standard 
allergy tests have high sensitivity, but in themselves do not signify disease. For example, a 
considerable proportion of such defined sensitised individuals have no evidence of asthma(13), and 
a positive test in an asthmatic patient does not always result in clinical response upon allergen 
exposure. Thus, there is a difference between allergic asthma with asthma symptoms induced by 
exposure to a defined allergen, and asthma in a subject characterized as “sensitised” with no 
relation between allergen exposure and clinical reaction. It has been suggested that a positive 
allergy test (assessed either by sIgE or SPT) should not be considered as a sole diagnostic marker of 
atopic sensitisation(14). 
 
Quantification of atopic sensitisation increases the specificity in relation to asthma presence and 
severity  
The last decade has seen the shift in the way we interpret the results of IgE and SPTs. The sum of 
the levels of specific IgE antibodies (or the summative size of SPT wheals) to inhalant allergens is a 
better predictor of the onset, presence, persistence and severity of childhood asthma than the mere 
presence of a “positive allergy test”(15-17). The clinical importance of “quantitative atopic 
sensitisation” has been confirmed in subsequent studies in adult asthma(18). It is now recognized 
that quantification of atopic sensitisation in early life amongst young children with wheezing is one 
of the best discriminators to identify those who are at high risk of subsequent development of 
persistent asthma(19).  
Additionally, a clear quantitative relationship between the level of sIgE and the size of SPT 
responses has been observed in relation to asthma severity, both in adults and in children(20, 21). 
For example, one of the phenotypic characteristics of severe treatment-resistant asthma (STRA) in 
childhood is the large size of SPT wheals to inhalant and food allergens. In patients with STRA, 
results of sIgE measurements and SPTs are not always concordant, indicating the need to carry out 
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both tests(17, 20). The level of sIgE is also associated with an increased risk of severe asthma 
exacerbations requiring hospitalization among both children(17, 22) and  adults(23). Finally, it has 
been shown that there is a strong interaction between the levels of sIgE to inhalant allergens and 
respiratory virus infections in increasing the risk of severe asthma exacerbations requiring hospital 
admission(24), suggesting a synergism between quantitative sensitisation and respiratory virus 
infections. This synergism has been indirectly confirmed in a study showing that pre-seasonal anti-
IgE- targeted therapy with omalizumab decreases seasonal exacerbations of asthma (“back-to-
school asthma”), which are almost certainly (rhino)virus-induced(25). In contrast, a recent study 
showed that although impaired IFN-β and IFN-λ induction by rhinovirus was a feature of bronchial 
epithelial cells from highly sensitised children with STRA(26), there was no relationship between 
sensitisation and Th2-mediated inflammation with impaired interferon production, raising a 
possibility of two independent mechanisms (atopy-related and virus-related). 
All of the above data indicate that in the assessment of patients with asthma (including severe 
asthma), the results of specific IgE measurement and SPT are not mutually exclusive but 
complementary, and should not be reported as being “positive” or “negative”, but as the level of 
sIgE and the size of SPT wheal diameter (i.e., quantified). For SPTs, the size of the positive and 
negative control should be taken into account. Recent data suggest that diagnostic accuracy of 
specific IgE antibody measurement in the context of asthma and the distinction between “benign” 
atopy (i.e., sensitisation in the absence of allergic symptoms) and “pathologic” atopy (i.e., 
sensitisation related to allergic symptoms), may be improved by the measurement of allergen-
specific IgG antibody levels(27), although their measurement is not recommended routinely. 
 
Heterogeneity of atopic sensitisation 
It has recently been proposed that “atopic sensitisation” maybe an umbrella term for a collection of 
several different subgroups of sensitisation which differ in their association with asthma and other 
allergic diseases(14). Distinct subgroups (or classes) of sensitisation were described in one 
population-based birth cohort (Manchester Asthma and Allergy Study) by applying a machine 
learning approach with Bayesian inference to the SPTs and sIgE data collected longitudinally from 
early life to school age(28), and similar latent structure was subsequently described using 
comparable approach to longitudinal data on atopic sensitisation in another birth cohort (Isle of 
Wight study)(14). Children who would be considered sensitised using conventional definitions were 
clustered into four distinct subgroups characterised by a unique pattern of the responses to different 
allergens and the timing of onset of allergen-specific sensitisation(28) (Figure 1). Importantly, the 
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risk of asthma was increased more than 20-fold amongst children belonging to one of these 
subgroups (those sensitised to multiple allergens in early life - comprising less than one third of the 
sensitised children), but not amongst those in other classes(14, 28). Striking similarities were 
observed in the association between different subgroups of atopic sensitisation in these two cohorts 
in relation to asthma severity, with children in the subgroup of sensitisation characterised by IgE 
responses to multiple allergens in early life having higher FeNO levels, more hyperreactive airways, 
an increased risk of severe asthma exacerbations having significantly diminished lung function, 
compared to all other classes(14, 28, 29). It is of note however, that such subtypes (clusters/classes) 
of sensitisation can only be identified using statistical inference on longitudinal data(14, 28), and 
that differentiation between different clusters at any single cross-sectional point is not yet 
possible(30). Clinical translation of this important observation requires the development of specific 
and sensitive biomarkers which can be measured at the time of presentation to clinic and which aid 
differentiation between different sensitisation subgroups. Recent data indicate that IgE responses to 
individual allergenic molecules rather than whole allergen extracts may prove useful in 
differentiating the subtypes of sensitisation relevant to asthma onset and severity(31, 32). 
 
Progression from Atopic Dermatitis to Allergic Asthma – fact or myth? 
Although atopic dermatitis (AD) usually precedes allergic asthma or rhinitis, a clear causal 
relationship for the typical sequence in the development of these diseases – formerly termed as the 
‘atopic march’ – remains to be confirmed. Recent analysis among 10,000 children followed from 
birth to school age, has demonstrated that, whilst point prevalence data for the whole population 
may show a profile consistent with the atopic march, modelling within individual data over the life 
course shows seven different patterns, with >94% of children with symptoms (AD, wheeze and 
rhinitis) during childhood not following the atopic march profile(33). Therefore, the atopic march 
may be just an epiphenomenon of different allergic subtypes occurring at similar time points of the 
individual development (co-manifestation), e.g. early-life wheeze and early-life sensitization. 
Evidence from longitudinal studies suggests that approximately one-third of patients with AD 
develop asthma and two-thirds develop allergic rhinitis support the hypothesis of an underlying 
common mechanism. A review of four population-based cohort studies with a minimum of 80% 
follow-up, confirmed that early-life AD (especially IgE-associated AD) is a significant risk factor 
for developing asthma later in life (pooled OR 2.14; 95% CI 1.76–2.75)(34). Interestingly, in two of 
these cohorts, the significant association of early-life eczema and asthma disappeared when 
adjusted for early-life wheeze and sensitization, but was still present when adjustment was confined 
to early-life wheeze, suggesting that sensitization is a major common factor. It also points to a 
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putative mechanism where AD may increase the risk of subsequent sensitization, which in turn 
increases the risk of asthma.  
Filaggrin gene (FLG) mutations are associated both with atopic and nonatopic eczema starting in 
the first year of life. FLG mutations combined with eczema in the first year of life are associated 
with a later development of asthma and hay fever, and this may support the latter 
mechanism(35). This more modern view of the atopic march is furthermore strongly supported by 
recent data on the defective skin barrier function as the key factor for the pathogenesis of AD(36). 
Skin barrier dysfunction facilitates transdermal dehydration and infiltration of allergens, bacteria 
and bacterial toxins, thus inducing and enhancing allergen sensitization as a hallmark of the atopic 
march(37). Skin sensitization is followed by airway sensitization to the same allergen and is one of 
the most robust predictors for the development of childhood asthma(38). This is detailed further on 
in this review. In conclusion, there is evidence for the hypothesis linking AD as an initial (but 
probably not only) promoter of atopy/allergic sensitization with progression to asthma.  
 
Component-resolved diagnostics in asthma 
Recent advances in biochemistry and molecular biology have led to the isolation and 
characterisation of numerous allergenic proteins (components), facilitating the profiling of IgE 
reactivity to individual allergens at a molecular level. This new approach to allergy diagnosis has 
been termed molecular diagnosis or component-resolved diagnostics (CRD), and its 
commercialisation has facilitated the development of products in which sIgE to >100 allergen 
components can be measured simultaneously. Component resolved diagnostics may help in 
identifying patients at risk of developing more severe disease(31, 32). Sensitization to mite 
allergens Der p 2 and Der f 2 has been reported to be more common in severe asthma (39). Latex 
allergy and asthma is another example were sensitization to 3 out of 12 recombinant natural rubber 
antigens (5, 6.01/6.02), was strongly linked to those with latex sensitization and asthma (40) 
The role of these novel tools in clinical practice and how best to interpret the complex data they 
generate is the subject of ongoing debate(41, 42). It has recently been reported that CRD may 
improve the assessment of asthma(31, 43), and help better understanding the role of allergy in 
severe asthma in childhood(44). However, it is likely that better interpretation algorithms are 
needed to capitalise fully on the potential of this exciting new technology(43).  
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SIMILARITIES AND DISTINCTIONS BETWEEN ADULT AND PAEDIATRIC SEVERE 
ASTHMA 
 
A fundamental feature of severe asthma in both adults and children is its heterogeneity, with 
multiple clinical phenotypes(6, 45-50). When unsupervised cluster analyses are performed, whether 
in adults or children, several common clinical features provide phenotypic distinctions, including 
the age of onset of disease, presence of co-morbidities, differences in lung function and the degree 
of atopic sensitisation(50-52). Using this approach, it appeared that the role of atopic sensitisation 
might be more important in the pathogenesis of severe asthma in early life. Severe atopy, 
characterised by polysensitisation and high specific IgE levels, is integral to childhood severe 
disease, such that >85% of children with severe asthma are severely atopic(53). In concurrence, 
when phenotypic clusters are investigated in adults with severe asthma, the single most important 
factor that repeatedly distinguishes the importance of allergy is age of disease onset(45). The 
phenotype of childhood onset asthma is robust, is repeatedly identified in adult cluster analyses and 
is undoubtedly associated with very severe allergic disease(8). In contrast, severe adult onset 
asthma is a distinct phenotype that is usually not characterised by atopic sensitisation, but often 
associated with nasal polyposis and sputum eosinophilia(54). 
 
Atopy and paediatric severe asthma 
The importance of early atopic sensitisation contributing to childhood severe asthma is reflected in 
the evidence of early sensitisation in preschool children being the main predictor of asthma 
development by school age(19, 55). In addition, even though recurrent wheezing episodes caused 
by rhinovirus infections in the first 3 years of life strongly predict asthma development(56), early 
atopic sensitisation is the main risk factor determining progression to asthma(56). Moreover, the 
pattern of atopic sensitisation to inhalant allergens, in particular to perennial ones, and the level of 
specific IgE increase asthma risk(57). 
The significant contribution of allergy to the pathogenesis of paediatric severe asthma is apparent 
from the clinical features that distinguish patients with difficult asthma (who have underlying 
modifiable factors) from those with genuine severe therapy resistant asthma (STRA)(58). 
Significantly, more patients with STRA are polysensitised, and have food allergy. Perhaps the most 
important distinctive feature of STRA becomes apparent when atopic sensitisation is quantified(18, 
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59). Patients with severe asthma have a much higher allergic burden(51, 60) suggesting that atopic 
sensitisation plays a critical role in the development, progression and persistence of paediatric 
severe disease.  
 
Adult onset, severe asthma: an age-specific phenotype 
Adult onset asthma is a recognised phenotype of severe asthma, presenting with several sub-
phenotypes(61). Although it is considered predominantly non-allergic, a significant proportion of 
patients with adult onset disease are atopic (34%)(61). In those with severe disease, a worse 
prognosis is apparent in smokers and ex-smokers(62), and, as described later on, smoke exposure 
has a detrimental effect on severe asthma, resulting in reduced corticosteroid responsiveness, 
regardless of age(63). Distinguishing and specific features of adult onset asthma include association 
with co-morbidities, such as obesity, and a predominance in middle-aged women(64). The adult-
onset obese, female predominant phenotype is characterised by the absence of inflammation and 
atopic sensitisation. Although this specific set of features is seen in adults, mechanisms resulting in 
obesity-associated asthma may not be dissimilar in children and adults. Children with severe asthma 
who have a higher BMI are less likely to have detectable inflammatory Th2 cytokines and have 
relatively higher lung function than those with lower BMI(53). 
Another common adult-onset phenotype includes severe (non-allergic) eosinophilic phenotype, 
which is the most prevalent phenotype of severe asthma in adults, associated with aspirin 
sensitivity, nasal polyposis and eosinophilia, all persisting despite the treatment with high doses of 
inhaled corticosteroids(54). Innate immune mechanisms underlying this phenotype have recently 
been proposed since it has become apparent that patients respond to anti-IL-5 antibody 
therapies(65). 
 
Contribution of allergy to mechanisms underlying severe asthma 
The role of allergy in severe asthma needs to be understood to help identify underlying mechanisms 
of disease progression which will impact both on the choice of add-on therapies and on the 
discovery of novel therapeutics. Even though the majority of children and adults with early-onset 
severe asthma are sensitised, it is interesting that not all respond to treatment with omalizumab(66, 
67)suggesting several different mechanisms contributing to the development of different allergic 
phenotypes. 
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Typically, the allergic asthma phenotype is associated with eosinophilia, elevated serum IgE and 
Th2 cytokines. However, in adult-onset asthma, eosinophilia may be present without overt evidence 
of allergy(65). The limited contribution of allergy to disease persistence is apparent in adults with 
severe asthma who show a non-allergic, inhaled corticosteroid “resistant” eosinophilic phenotype, 
which responds to systemic CS and targeted therapy with anti-IL-5 (mepolizumab)(68). Novel 
mechanisms that may contribute to this adult-onset phenotype include epithelial innate cytokines 
that directly induce the recruitment of innate lymphoid cells which secrete Th2/“allergic” cytokines 
without the generation of IgE or an adaptive immune response(69). Interestingly, even though it is 
thought that this is an innate, non-adaptive, non-allergic immune response, all murine experimental 
models investigating the role of innate cytokines in asthma pathogenesis used allergen exposure as 
the stimulus, suggesting allergy still plays a central mechanistic role in this phenotype(70). It is 
possible that allergy is a risk factor in the development of adult-onset “non-allergic” eosinophilic 
asthma, but the clinical manifestation of asthma changes with time and age, whereby it is less 
overtly “allergic”, but remains eosinophilic. 
In asthma, the effect of innate immunity eliciting Th2 responses seems to be strongly related to IL-
33(71), and is especially associated with severe disease. IL-33 expression is increased in bronchial 
tissue from both adults(72, 73) and children(74)with severe asthma. Other important features of 
innate cytokines that may contribute to the pathogenesis of severe disease in both adults and 
children include their role in (relative) corticosteroid resistance(74) and their association with 
angiogenesis and airway remodelling, in particular as regards IL-25 (74-76).  
An interesting distinction of adult asthma phenotypes based on gene expression of periostin by 
airway epithelial cells includes the separation in Th2 high and Th2 low phenotypes(77), and the 
utility of this biomarker to predict therapeutic response to antibodies that block Th2 cytokines(78). 
Although biomarkers that allow such distinctions have not yet been identified in children, and while 
in general children with severe asthma have low or undetectable Th2 cytokines in airway samples, 
there is a sub-group in whom Th2 cytokines can be detected(53), emphasising similarities between 
adult and childhood disease. 
 
 
CROSS-TALK BETWEEN ENVIRONMENTAL FACTORS, ATOPIC SENSITISATION 
AND ASTHMA 
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The airway epithelial barrier 
Environmental stimuli, such as viruses, bacteria and air pollutants, are known activators of innate 
immunity and may thus enhance the airway inflammation in asthmatic patients. Allergens, apart 
from being recognised by the adaptive immunity, may also play a crucial role in activating innate 
immunity through proteases, biologically active glycolipids and enzymes(79). The airway epithelial 
barrier, for long time perceived as only a mechanical barrier, is now also recognised as a gate to 
initiate atopic sensitization and allergic inflammation(80). Epithelial cells recognise the allergens 
with the help of pattern recognition receptors and produce an innate immune response. As apical 
junctional complexes between the airway epithelium cells are being disrupted by viral infections 
and inhaled airway irritants, they facilitate the entry of allergens from the lumen to be presented to 
the dendritic cells.  
In bronchial biopsies and brushings especially from more severe asthmatic patients, airway 
epithelium cells showed structural and functional defects in apical junctional complexes compared 
to healthy controls(81). However, this reduced barrier function was found to be reversible by 
epidermal growth factor (EGF) treatment(81). 
 
The role of microbiota 
Early life airway and gut microbiota and influencing factors such as the delivery method, feeding 
practices, antibiotic use and living environment were shown to be related with allergic asthma 
development(82). Both the microbial burden and diversity within the lower airways were shown to 
be significantly higher in suboptimally controlled asthmatic patients compared to healthy 
individuals(83). Protobacteria species significantly predominated in asthmatic patients using 
inhaled corticosteroids and showed the strongest correlations with the degree of bronchial 
hyperresponsiveness(82). In addition, corticosteroid resistance in asthmatic patients was found to be 
related to airway microbiome diversity(84). In these patients, Haemophilus parainfluenza 
dominated the microbiome, and was shown to inhibit the response to corticosteroid treatment 
compared to corticosteroid responsive asthmatic patients. Microbial diversity was also shown to 
increase the risk of rhinovirus-induced asthma exacerbations in children(85). If rhinovirus existed 
concomitantly with Moraxella catarrhalis, Streptococcus pneumoniae, or Haemophilus influenzae 
within the airways, the risk of asthma exacerbations was found to be significantly increased as 
compared to children without these pathogens. 
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Viruses 
The interaction between viral lower respiratory tract infections (LRTI) and atopic sensitization has 
been recognized as a major factor contributing to asthma development and exacerbation(86, 87). 
Birth cohort studies provide strong evidence for a synergistic effect of viral LRTI and atopic 
sensitization on asthma inception particularly in predisposed children(56, 88). Other factors 
reported to increase the risk of asthma development include the type of virus (more than 10-fold 
increased risk for asthma development with rhinovirus compared to 5-fold with respiratory 
syncytial virus), the severity of viral LRTI, the age during viral LRTI and the atopic 
predisposition(89). Very recently, the number of respiratory episodes in the first years of life, but 
not the particular viral trigger, was reported to be associated with later asthma development(90). 
Respiratory viral infections in combination with atopic sensitisation and exposure to allergens 
increase the risk of hospital admission due to asthma exacerbation both in children(91) and 
adults(92). Rhinoviruses (RV), especially RV-C group, are the most frequent viruses detected 
during an asthma exacerbation(22)including severe asthma exacerbations with near fatal and fatal 
asthma(23). Also, allergic asthmatic individuals experience more severe and prolonged LRTI 
symptoms with RV infection compared to non-atopic healthy controls(93). Biological mechanisms 
including impaired innate or altered adaptive immune function, abnormal airway structure and 
function following prior infections, genetic influences and extrinsic factors, such as maternal 
smoking, air pollution and nutritional factors (vitamin D), may explain the altered immune response 
to viral infections in asthmatic/allergic patients(87). Recently, antibody titers to species specific RV 
infection in children during asthma exacerbation showed that antibody response to RV-C is low 
even when the virus was detected, pointing to a divergent and possibly less efficacious immune 
response to this subtype compared to RV-A and B(94). The association of susceptibility to RV 
infection in asthma was also investigated in human bronchial epithelial cells showing impaired 
interferon production to the virus in severe therapy resistant allergic asthmatic children(26) but 
normal responses in well controlled asthmatic adults who were mostly atopic(95). In contrast to RV 
data, interferon responses to influenza A virus and RSV in human bronchial epithelial cell cultures 
were preserved in adults with mild to severe asthma(96).  
 
Outdoor, indoor and food allergens 
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Relationships between different types of allergens (outdoor, indoor, food) and the development and 
severity of allergic disease, including asthma, have been studied(97). For instance, pollen allergy 
has been found to be interrelated with various food allergies, digestive system Th2-inflammation 
and asthma(98, 99). Cross-reactivity between pollen and several plant-derived foods, nuts, and 
fruits has been well established(98). Food allergy without concomitant asthma has been found to be 
associated with increased nonspecific bronchial  hyperresponsiveness(100, 101), while several 
studies report that children with asthma and concomitant food allergy have more severe disease, 
poorer control, greater morbidity, and require more anti-asthma medications(102, 103). 
The most common indoor allergens associated with asthma include house dust mites, domestic 
animals (cats, dogs), and cockroaches(97, 104), while fungi can be found both indoor and outdoor. 
In a cohort of 300 asthmatic children (aged 4-12 y), higher Der p 1 and pet allergen levels were 
found to be associated with greater asthma severity(105). 
Fungal exposure is universal and fungi can be linked to asthma in a variety of ways. Fungal allergy 
drives asthma severity and long-term or uncontrolled fungal infections are associated with a poor 
control of asthma, complications such as bronchiectasies and chronic allergic bronchopulmonary 
aspergillosis (ABPA)(106).  In the general asthma population, sensitization to moulds ranges from 7 
to 20%, in severe asthma patients from 35 to 75%, being 54-91% in life-threatening asthma 
population(107-111). The first evidence of the link between the severity of asthma and fungal 
sensitisation dates to 1978, when Schwartz et al. demonstrated a relationship between asthma 
severity and Aspergillus spp sensitisation(112). Alternaria or Cladosporium spp sensitisation was 
associated with asthma severity in the European Community Respiratory Health Survey. 
Furthermore, a recent paper has shown that fungal sensitisation in children with persistent asthma is 
associated with disease severity(113)and a 2014 review has shown increasing evidence that 
sensitized asthmatic children may be susceptible to asthma exacerbations when exposed to outdoor 
fungal spores and that the severity of exacerbation may vary with different fungi species(114). 
The term “Severe Asthma with Fungal Sensitisation” (SAFS) was introduced by Denning et al. in 
2006, to describe those patients who have persistent severe asthma (despite standard treatment) and 
evidence of fungal sensitisation, as defined by positive SPT, or fungus or fungal antigen-specific 
sIgE, and do not meet the criteria for ABPA(10). Proposed classification by an EAACI Task Force 
sets the total IgE cut-off at <1000 IU/ml for SAFS and >1000 IU/ml for ABPA. ABPA was 
accepted as an endotype(115), while SAFS remains a pragmatic definition(106). ABPA may 
develop in asthmatics with a genetic predisposition and therefore SAFS may have the same 
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background. Carefully genotyping patients with different forms of asthma may allow a better 
understanding of this disease. 
“Trichophyton Asthma” is another clinical entity, where inhalation or the presence of cutaneous 
infection (athlete’s foot, onychomycosis) in sensitised asthmatics is associated with disease 
severity(106, 116). 
 
Smoking 
Cigarette smoking itself may influence asthma, as it accelerates lung function decline(117), impairs 
the response to CS (both inhaled and oral)(118), increases airway oxidative stress(119),  perpetuates 
symptoms despite of treatment(120) and induces the change of inflammatory phenotypes into more 
aggressive ones(121),  thereby resulting in a more severe disease(122). 
Smoking also increases serum IgE levels, especially in men(123). This may result in an increased 
risk of allergic sensitisation, at least for occupational allergens(124). However, the relationship 
between cigarette smoking and allergy in severe asthma is still debated: some studies identify 
smoking as a risk factor for allergic asthma(125), while others show a lower prevalence of atopic 
sensitisation in smoking patients with severe asthma(121). According to a large epidemiological 
survey (ECRHS II), smoking was more strongly associated with severe asthma in men than in 
women, particularly if they were sensitised to moulds (Cladosporium), house dust mites or 
cats(126). Even more conflicting data come from studies on the effect of passive smoking on the 
risk of development of atopic sensitisation(127). 
Cigarette smoking usually results in a more neutrophilic airway inflammation, which is less 
responsive to ICS(121). Accordingly, alveolar macrophages from smokers have a reduced cellular 
CS responsiveness, which is associated with reduced histone deacetylase activity, an essential 
molecule for anti-inflammatory genes transcription(63, 128). In fact, they show an elevated 
glucocorticoid receptors (GR) ratio in PBMC which is in favour of GR-β (not able to induce any 
transcriptional activity) compared to GR-α (the active isoform with anti-inflammatory effects)(129). 
These molecular events make smoking asthmatics less responsive to CS, currently the standard 
controller therapy for asthma, leading them to a more probable evolution to severe asthma (figure 
2). 
Recently, a new distinct phenotype of severe asthma has been identified in frequent exacerbators, 
and history of smoking seems to be a risk factor for this phenotype(130). A novel risk score for 
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asthma exacerbations developed and validated by Bateman et al. supports the evidence that 
smoking status is a main predictor for uncontrolled asthma(131). Despite this well-known 
relationship, active smoking is still surprisingly common among asthmatics(132). More efficient 
smoking prevention programs and smoking cessation campaigns should be carried out to try to 
reduce the risk of developing severe asthma. Moreover, most clinical trials with new drugs aimed 
for severe asthma have been conducted in non-smoking patients, which results in incomplete 
knowledge on the efficacy of such therapeutic approaches in smokers. Large “real life” studies in 
severe asthma including smoking asthmatics should be encouraged. The complex relationship 
between cigarette smoking and atopic sensitisation increasing the risk of severe asthma should be 
better investigated as only few and conflicting data are presently available. However, this 
relationship remains difficult to address, particularly in cross-sectional studies, because of the 
potential selection bias (e.g. “healthy smoker effect”)(133). Prospective studies in lifetime smokers 
with lifetime smoking are more appropriate to properly examine the relationships between smoking 
and severe asthma. 
 
Pollution 
The health effects caused by outdoor air pollution have been intensively studied during the last 
decades. The term “outdoor air pollution” involves particulate matter (PM), gaseous pollutions 
(nitrogen dioxide, sulphur dioxide and ozone) and traffic-related air pollution (elemental and carbon 
black, road dust)(134). 
Increased exposure to ultrafine particles and carbon monoxide within the previous 4-7 days was 
associated with increased relative odds of a paediatric asthma visit(135). Other studies also indicate 
that sudden increase or decrease of exposure to air pollution may affect asthmatic symptoms or 
emergency department visits(136-138). Indeed, a decrease in the number of acute asthma events of 
over 40% was found after reduction of air pollution during summer Olympic games(138). So far, 
these studies were performed in children and included only a relatively low number of individuals. 
Larger scale studies also demonstrated an adverse effect of outdoor air pollution on lung 
function(139-141). A multicenter birth cohort study (ESCAPE) showed an association between 
estimated levels of NO2 and PM2.5and decreases in FEV1(139). In another birth cohort study 
(MAAS), lifetime exposure to PM10 and NO2 was associated with significantly less growth in FEV1 
over time(140). In the same cohort, no association was found between long-term exposure to PM10 
and NO2 and the prevalence of asthma or wheeze(142). In adult asthmatics, exposure to NO2 and 
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PM10 was associated with lower measures of FEV1 and FVC(143)and exposure to ozone and PM10 
increased the risk of uncontrolled asthma(144). Overall, these studies thus provide evidence of an 
inverse association between outdoor air pollution and lung function (Table 1). Whether asthma 
severity is directly affected by outdoor air pollution is unclear. 
Several studies showed a positive association between exposure to air pollution during infancy and 
sensitisation to inhalant allergens(145-147). Although the mechanism underlying this association is 
not fully understood, some evidence suggests that ultrafine carbon black particles can directly 
induce maturation of dendritic cells in vitro(148), thereby facilitating sensitisation to inhalant 
allergens. Alternatively, airborne pollutants can induce the influx of inflammatory cells to the lungs, 
which might then lower the threshold for sensitisation. Indeed, it has recently been shown that 
allergen-specific Th2/Th17 cells accumulate in the lungs of mice exposed to both diesel exhaust 
particles and house dust mite extract(149). Diesel exhaust particles may also produce other 
immunological effects(150, 151) (Table 2). Furthermore, exposure to moderate air pollution during 
late pregnancy was found to cause increased cord blood IL-1β(152). A recent meta-analysis, 
however, showed no clear overall association between air pollution exposure and the development 
of sensitisation in children up to 10 years of age(153). 
In summary, in multi-sensitised asthmatics, daily exposure to allergens in combination with other 
enhancing factors, including viral infections, environmental smoking, and/or pollution, will finally 
determine the asthma course and severity. 
 
Occupational/Work-Related 
Severe asthma may occur in patients affected by Work-Related Asthma (WRA).WRA encompasses 
both Occupational Asthma (OA), defined as “asthma caused by the workplace” and “Work-
Exacerbated Asthma” (WEA), occurring in patients with pre-existing or concurrent asthma and 
exacerbated by different work-related factors (i.e. aeroallergens, exercise, irritants)(154). OA can be 
further divided into two subtypes: an allergic form (90% of all OA)(155), caused both by an IgE-
mediated mechanism towards high (HMW) and low (LMW) molecular weight agents(106), and a 
non-IgE mediated form (Non-Allergic, Irritant-Induced [Occupational] Asthma (IIOA)), towards 
specific LMW agents in which the mechanism has not been characterized yet. The non-allergic 
IIOA can be further divided into the “Reactive Airway Dysfunction Syndrome” (RADS) and the 
“IIOA after multiple exposures”. The first occurs after an acute, single exposure to very high 
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concentrations of irritating substances(156), while the second follows multiple exposure to irritants; 
in this subtype, onset of asthma can follow the exposures after some time(157, 158). 
WRA should be suspected in patients whose asthma worsens while working or begin at work. Here 
a detailed occupational and medical history is fundamental(159, 160), while a clinical history only 
shows a low specificity in the diagnosis of OA(161). The investigation of WRA follows a well-
defined protocol based on confirmation of bronchial asthma, work-related bronchoconstriction, 
sensitisation to occupational agents and on the confirmation of the causal role of occupational 
agents, being sensitisation per se not indicative of clinical symptoms(162) (Figure 3). Baseline 
spirometry is mandatory and it is strongly recommended that this should be complemented with 
non-specific bronchial hyperreactivity assessment with direct or indirect challenges. In individuals 
with suspected WRA, presenting with a normal respiratory function and/or negative methacholine 
challenge testing, serial lung function measurements and assessment of non-specific bronchial 
hyperreactivity are strongly recommended(162, 163). Additionally, spirometry can be performed 
during a work shift (Cross-shift spirometry). Furthermore, serial measurements of peak flow 
expiratory rate (serial PEFR) have been used to objectively confirm the link between the workplace 
and the asthmatic symptoms(164). Skin prick testing completes the diagnostic work-up, and the 
selection of specific allergens related to the individual’s job is fundamental. Specific IgE evaluation 
is also of importance. The role of atopic mechanisms in severe occupational asthma has been 
confirmed by a recent study where treatment with omalizumab was successful in 90% of severe 
occupational asthma patients due to HMW and LMW agents, such as flour, animal dander, mites, 
moulds, isocyanate or acrylates(165). It is worth noting that, at least in OA, allergen exposure levels 
represent the major determinants both for the disease as such and for the severity of asthma(166, 
167). Finally, specific inhalation challenges (SICs) or workplace inhalation challenges, 
complemented by the assessment of airway inflammation by induced sputum and FeNO may be 
considered. 
Diagnosis of IIOA follows a well-defined protocol described in a recent EAACI Task Force 
document(158).  
 
 
CONCLUSION 
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There is increasing evidence for the important, but not exclusive, role of allergy in severe asthma. 
Although some recent reports demonstrate that allergy may play only a limited role, this is likely 
not true for childhood disease, where early atopic sensitisation is critical in determining the severity 
of disease. 
Mechanistic implications of co-factors interacting with allergy and asthma, such as virus infections, 
pollution, smoking, and work-related exposures, still need to be completely uncovered to allow the 
discovery of novel therapeutic targets. 
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Figure 1.  For those children who suffered a hospital admission with wheeze or asthma after age 3 
years, a highly significant increase in the risk was seen only among children in the multiple early 
sensitisation subgroup (HR 9.2; 95% CI, 3.5–24; P < 0.001), but not other atopy classes.  
From (28): Simpson A, Tan VY, Winn J, et al. Beyond atopy: multiple patterns of sensitization in 
relation to asthma in a birth cohort study. Am J Respir Crit Care Med 2010;181(11):1200-6, with 
permission 
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Table 1: Main pollutants and examples of their effects on respiratory function. 
Pollutant Outcome 
  
Nitrogen dioxide (NO2) Decreased FEV1(139) 
 Less growth of FEV1 over time(140) 
 Lower measures of FEV1(143) 
 Lower measures of FVC(143) 
PM2.5 Decreased FEV1(139) 
PM10 Less growth of FEV1 over time(140) 
 Lower measures of FEV1(143) 
 Lower measures of FVC(143) 
 Increased risk of uncontrolled Asthma(144) 
Ozone (O3) Increased risk of uncontrolled Asthma(144) 
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Table 2: Pollutants and examples of their effects on allergic inflammation 
Pollutant Outcome 
  
Ultrafine Carbon Black Particles
 
Induced maturation of Dendritic Cells in vitro (148) 
Diesel Exhaust Particles and 
House dust Mite Extract 
Increased allergen-specific IgE and other cardinal features of 
asthma (150) 
 
Accumulation of allergen-specific Th2/Th17 cells in lungs 
(149) 
 
Both Th2 and ILC2 contribute to DEP-enhanced airway 
inflammation (151) 
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Figure 2: Influence of smoking and atopy in determining more severe asthma. 
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Figure 3: Allergic Occupational Asthma: diagnostic flow-chart. 
From: Moscato G, Pala G, Barnig C, De Blay F, Del Giacco SR, Folletti I, et al. EAACI consensus 
statement for investigation of work-related asthma in non-specialized centres. Modified from: 
Allergy. 2012;67(4):491-501, with permission. 
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